# A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

> **NCT07232524** · PHASE1 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 16 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Solid Tumor

## Interventions

- **DRUG:** BL-M24D1

## Key facts

- **NCT ID:** NCT07232524
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-10
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07232524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07232524, "A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07232524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*